Resveratrol for Heart & Circulation

Resveratrol became a household word because of the heart. In the early 1990s the "French paradox" — the observation that the French seemed to have relatively low rates of coronary heart disease despite a diet rich in saturated fat — was popularized on American television and pinned, plausibly but loosely, on red wine and its polyphenols. That single story launched a supplement industry. This page separates what is real from what is folklore: the paradox itself is now widely regarded as largely a statistical artifact; the genuine vascular effects of resveratrol (on the endothelium, blood pressure, platelets, and inflammation) are real but modest, mostly measured on surrogate markers, and mostly demonstrated at supplement doses far beyond anything a glass of wine could ever deliver.

Table of Contents

  1. The Cardiovascular Claim
  2. The French Paradox — Mostly a Myth
  3. Endothelial Function and Nitric Oxide
  4. Blood Pressure
  5. Cholesterol and Lipids
  6. Platelets and Clotting
  7. Inflammation in Coronary Artery Disease
  8. The Dose and Bioavailability Problem
  9. Honest Bottom Line
  10. Cautions and Interactions
  11. Key Research Papers
  12. Connections
  13. Featured Videos

The Cardiovascular Claim

The mechanistic case for resveratrol as a cardiovascular protectant is genuinely attractive on paper. In laboratory models it relaxes blood vessels by increasing nitric oxide, blunts the oxidation of LDL cholesterol, discourages platelets from clumping, quiets the inflammatory signaling that drives atherosclerotic plaque, and switches on the same SIRT1 and AMPK pathways that mediate the cardiovascular benefits of exercise. If all of these translated cleanly into humans at achievable doses, resveratrol would be a remarkable drug.

The reality is more sober. Almost every human cardiovascular trial of resveratrol has measured surrogate endpoints — a number on a machine (flow-mediated dilation, blood pressure, an inflammatory marker) rather than a heart attack prevented or a life extended. Surrogate improvements are encouraging but not the same as clinical benefit; the history of cardiology is littered with drugs that improved a surrogate and then failed to help, or even harmed, when tested on hard outcomes. No trial has ever shown that resveratrol prevents heart attacks, strokes, or cardiovascular death. That is the honest ceiling on everything below.

Back to Table of Contents

The French Paradox — Mostly a Myth

The phrase "French paradox" was popularized after Serge Renaud and Michel de Lorgeril published a 1992 Lancet analysis linking moderate wine consumption to lower coronary heart disease mortality, and after a widely watched 1991 television segment brought the idea to a mass audience. The intuitive story — a compound in red wine protects the French heart — is emotionally satisfying and almost certainly wrong as usually told.

Several later analyses have dismantled the paradox as a genuine biological puzzle:

Even if a modest real effect of moderate wine remains after all corrections, attributing it to resveratrol is a further leap that the evidence does not support. Any cardiovascular benefit of wine is far more plausibly attributed to ethanol's effects on HDL and clotting, to the broader polyphenol mix, or to the lifestyle that accompanies moderate drinking — and the resveratrol content of wine (see below) is far too small to be pharmacologically active. The French paradox is best understood as a cautionary tale about turning an epidemiological curiosity into a supplement.

Back to Table of Contents

Endothelial Function and Nitric Oxide

The endothelium — the single-cell lining of blood vessels — controls vascular tone by releasing nitric oxide (NO), a gas that signals the smooth muscle in the vessel wall to relax. Healthy endothelial function is an early casualty of aging, diabetes, and atherosclerosis, and it can be measured non-invasively as flow-mediated dilation (FMD): how much the brachial artery widens after a brief cuff occlusion.

Resveratrol upregulates endothelial nitric oxide synthase (eNOS) in cell and animal models, and several small human trials have reported acute and short-term improvements in flow-mediated dilation after resveratrol, sometimes in a dose-dependent fashion and often more pronounced in people who already have impaired vascular function (obese or diabetic participants). This is one of the more reproducible human signals for resveratrol.

The caveats are the familiar ones: FMD is a surrogate marker, the trials are small and short, and the effect size, while statistically detectable, is modest. Improved FMD is a reasonable hint that resveratrol does something real to the vasculature, but it is not evidence that it prevents cardiovascular events. For the disease processes this pathway matters in, see our pages on atherosclerosis and coronary artery disease.

Back to Table of Contents

Blood Pressure

Blood pressure is the cardiovascular endpoint where the human resveratrol data are clearest, precisely because it has been meta-analyzed. Liu and colleagues pooled six randomized controlled trials (247 participants) in Clinical Nutrition and reached a nuanced conclusion: across all doses, resveratrol did not significantly lower either systolic or diastolic pressure. In a subgroup analysis, however, higher doses (at or above 150 mg per day) produced a significant reduction in systolic pressure, with no effect on diastolic pressure.

The honest reading is that resveratrol has, at best, a small blood-pressure effect that requires a supplement-level dose and shows up mainly in systolic numbers. It is not a substitute for established antihypertensive therapy, weight loss, sodium reduction, or exercise, all of which have far larger and better-documented effects. It might be a minor adjunct in someone already taking it for other reasons. See our hypertension page for the interventions with the strongest evidence.

Back to Table of Contents

Cholesterol and Lipids

Resveratrol's effects on blood lipids are inconsistent. Some trials, particularly in people with existing coronary disease or diabetes, report small reductions in LDL cholesterol, oxidized LDL, or triglycerides; others find no change at all. A grape-extract supplement standardized to resveratrol reduced oxidized LDL and apolipoprotein B in statin-treated patients undergoing primary cardiovascular prevention in one of the Tomé-Carneiro trials — a genuinely interesting result, but one obtained with a whole grape-polyphenol extract rather than pure resveratrol, and in patients already on a statin.

The pattern across the lipid literature is that where resveratrol appears to help, the effect is small, is more likely in already-diseased populations, and is easily swamped by diet and by statin therapy. It should not be presented as a lipid-lowering agent.

Back to Table of Contents

Platelets and Clotting

Part of the original wine-and-heart hypothesis was antiplatelet: resveratrol inhibits platelet aggregation in vitro, reducing the tendency of platelets to clump and initiate a clot on a ruptured plaque. This is mechanistically real in the test tube and in animal models. In humans, the clinical relevance is uncertain, and it cuts both ways — a genuine antiplatelet effect would also mean an increased bleeding tendency, which is the basis for the drug-interaction cautions below. There is no evidence that dietary or supplemental resveratrol produces a clinically meaningful antithrombotic benefit, and no reason to use it in place of aspirin or prescribed anticoagulants where those are indicated.

Back to Table of Contents

Inflammation in Coronary Artery Disease

Atherosclerosis is now understood as a chronic inflammatory disease of the arterial wall, not merely passive cholesterol deposition. Resveratrol quiets inflammatory signaling (it inhibits the master inflammatory transcription factor NF-κB and reduces pro-inflammatory cytokines), which makes anti-inflammatory cardiovascular benefit biologically plausible.

The most cited human data come from the Tomé-Carneiro group in Spain, who ran one-year trials of a grape extract containing resveratrol in patients with stable coronary artery disease taking optimal medical therapy. They reported increased serum adiponectin (an anti-inflammatory, insulin-sensitizing hormone), downregulation of pro-inflammatory genes and microRNAs in circulating immune cells, and reductions in inflammatory markers. These are the most encouraging cardiovascular results in the literature — but they must be read with care: the trials were small, used a grape-polyphenol extract rather than isolated resveratrol, came largely from a single research group, and again measured inflammatory surrogates rather than clinical events.

Back to Table of Contents

The Dose and Bioavailability Problem

Every positive cardiovascular result above shares a hidden premise: the dose. Human trials that saw effects used roughly 150 mg to several hundred milligrams of resveratrol per day, sometimes more. Red wine contains only about 0.1 to 2 milligrams of trans-resveratrol per liter — so a typical 150 mL glass supplies on the order of a few tenths of a milligram. To reach even the low end of a trial dose from wine alone, a person would have to drink a physically impossible (and lethally alcoholic) volume. The wine-as-heart-medicine narrative fails on arithmetic before it fails on biology.

Compounding this, resveratrol taken by mouth is extensively converted to glucuronide and sulfate metabolites during first-pass metabolism, so the amount of free, active resveratrol circulating in the blood is very low even after a large supplement dose. This is the central reason the human cardiovascular effects are so much more modest than the cell-culture experiments predicted. See the Antioxidant & Cellular Protection page for the full pharmacokinetic story.

Back to Table of Contents

Honest Bottom Line

Back to Table of Contents

Cautions and Interactions

Back to Table of Contents

Key Research Papers

  1. Renaud S, de Lorgeril M (1992). Wine, alcohol, platelets, and the French paradox for coronary heart disease. The Lancet, 339(8808), 1523–1526. — PubMed 1351198
  2. Liu Y, Ma W, Zhang P, He S, Huang D (2015). Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clinical Nutrition, 34(1), 27–34. — PubMed 24731650
  3. Tomé-Carneiro J, et al. (2012). Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease. American Journal of Cardiology. — PubMed 22648627
  4. Tomé-Carneiro J, et al. (2013). One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines in patients with coronary artery disease. — PubMed 23557933
  5. Baur JA, Sinclair DA, et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444(7117), 337–342. — PubMed 17086191
  6. Walle T, et al. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition, 32(12), 1377–1382. — PubMed 15333514

PubMed Topic Searches

  1. PubMed: resveratrol & endothelial function
  2. PubMed: French paradox critiques
  3. PubMed: resveratrol & platelets
  4. PubMed: resveratrol & atherosclerosis
  5. PubMed: resveratrol & nitric oxide

Back to Table of Contents

Connections

Back to Table of Contents